Table 3: Results of medical chart review for patients on medication-assisted therapy, by treatment site.

IndicatorPavlodarTemirtauUst-Kamenogorsk

Proportion of patients on MAT with at least one complete clinical review in the last quarter000
Proportion of MAT patients screened for hepatitis B57%85%62%
Proportion of MAT patients screened for hepatitis C77%94%59%
Proportion of patients on MAT with at least one psychosocial counseling session during the last month21%51%94%
Proportion of patients who remained free from nonprescribed opioids1 six months after initiation of MAT95%68%95%
Proportion of patients on MAT remaining in care six months after initiation of MAT72%55%65%
Proportion of patients who remained free from nonprescribed opioids1 twelve months after initiation of MAT92%41%84%
Proportion of patients on MAT remaining in care twelve months after initiation of MAT61%46%61%
Proportion of patients on MAT with at least one sexual- and drug-related risk assessment completed during the last month0%0%0%
Mean daily dose of methadone received by patients enrolled in MAT for three months or longer, mg (standard deviation)66 (23,9)69 (22,7)73 (40,4)

1Based on urine toxicology test.